- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria. (ABIGAIL)
This study looks at new ways to treat advanced breast cancer that's hormone-sensitive. It tests if adding a short course of chemotherapy to existing hormone treatments can help shrink tumours more effectively.
For: HR-positive/HER2-negative breast cancerSpain · Portugal · Italy - Active not recruitingPHASE2, PHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study looks at a new drug, Inavolisib, combined with standard treatments (Palbociclib and Fulvestrant) for a specific type of advanced breast cancer. It compares this new combination to the standard treatments alone, checking how well it works and if it's safe.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
This study is looking at a new combination of medicines, Inavolisib and Fulvestrant, for people with a specific type of advanced breast cancer. It aims to see how well this combination works and if it's safe after other treatments haven't worked.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
This study is looking at a new combination of medicines for advanced breast cancer that has stopped responding to hormone therapy. It aims to see if combining inavolisib with ribociclib and fulvestrant works better than the current treatment.
For: Breast CancerUnited States · Argentina · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients withPIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments.
This study looks at new drug combinations for advanced breast cancer. It's for people whose cancer has a specific change (PIK3CA mutant) and has grown despite previous treatments. Researchers want to see if the new treatments can help people live longer without their cancer getting worse.
For: Adult patients with PIK3CA mutant · HR-positive · HER2-negative advanced breast cancerDenmark · Italy - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
This study is testing a new medicine, PF-07248144, with an existing one, fulvestrant, for advanced breast cancer that has grown despite previous treatment. It aims to see if this combination is safe and effective.
For: Breast CancerUnited States · Australia · Belgium - Active not recruitingPHASE1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
This study is looking into a new medicine, LOXO-783, for breast cancer and other solid tumours with a specific gene change (PIK3CA). It aims to understand if the medicine is safe, what side effects it has, and how well it works.
For: Breast CancerUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE1, PHASE2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.
For: Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid TumorsUnited States · Australia · Canada - RecruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
For: Breast Neoplasms · Neoplasm MetastasisUnited States · Argentina · Australia - Active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
For: Liposarcoma · Prostate Cancer · Breast NeoplasmsUnited States · Argentina · China - RecruitingPHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This study looks at a new drug, giredestrant, with an existing drug, everolimus, for advanced breast cancer. It compares this combination to standard hormone therapy plus everolimus, for people whose cancer has grown despite previous treatments.
For: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Germany - Active not recruitingPHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This study looks at how a drug called tucatinib, combined with trastuzumab, works for various cancers that have a specific change (alteration) in their HER2 gene. It focuses on cancers that have spread or can't be fully removed by surgery.
For: Uterine Neoplasms · Uterine Cervical Neoplasms · Biliary Tract NeoplasmsUnited States · Belgium · Germany - RecruitingPHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
This study is testing a new medicine, MK-5684, for breast, ovarian, and endometrial cancers. It aims to see if MK-5684, which blocks steroid hormones, can stop cancer from growing or spreading for longer than current standard treatments.
For: Malignant NeoplasmUnited States · Argentina · Brazil - RecruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
For: Solid TumorsUnited States · France · Italy - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
This study looks at two drug combinations, inavolisib with fulvestrant, and alpelisib with fulvestrant, for advanced breast cancer that has specific genetic changes and has already been treated with certain therapies. It aims to see which combination works better and is safer.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
This study is testing a new combination treatment for advanced breast cancer. It combines a drug called belzutifan with fulvestrant, comparing it to standard hormone therapy. The goal is to see if this new approach is effective and safe for people whose cancer has spread and is hormone-sensitive.
For: Metastatic Breast CancerUnited States · Argentina · Canada - Active not recruitingPHASE3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This study looks at new drug combinations for advanced breast cancer that has grown despite previous treatments. It compares different medications, including gedatolisib, fulvestrant, and palbociclib, to see if they are safe and effective.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.
For: Breast Cancer · Advanced Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
This study is testing a new medicine, ARV-471, against an existing treatment, fulvestrant, for advanced breast cancer that has spread. It's for people who have already had certain hormone therapies. The aim is to see if ARV-471 is safe and effective.
For: Advanced Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
For: Advanced Breast CancerUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.
This study looks at new ways to treat advanced breast cancer that has spread. It's for women with a specific type of hormone-positive breast cancer. Researchers are comparing two different drug combinations to see which works best at stopping the cancer from growing.
For: Metastatic Breast Cancer HR+ · HER2-France - Active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
For: Breast Cancer · Solid TumorUnited States · Canada · France - RecruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.
For: Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Metastatic Breast CancerUnited States · Spain · United Kingdom - Active not recruitingPHASE1, PHASE2
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
This study is for post-menopausal women with advanced breast cancer that has grown despite standard hormone treatment. It's testing a new drug, AZD5363, alongside an existing treatment, Fulvestrant, to see if it can stop cancer growth more effectively.
For: Estrogen Receptor Positive Breast CancerUnited Kingdom - Active not recruitingPHASE2
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
This study looks at a new drug, PF-07220060, combined with fulvestrant for advanced or metastatic breast cancer. It compares this combination to standard treatments to see if it's safe and effective for people whose cancer has progressed after previous therapies.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study looks at a new drug, AZD9833, for post-menopausal women with advanced breast cancer that's hormone-sensitive (ER-positive) and HER2-negative. It compares AZD9833, taken by mouth, with an existing injected drug, Fulvestrant, to see which is safer and more effective.
For: Advanced ER-Positive HER2-Negative Breast CancerUnited States · Belgium · Canada - Active not recruitingPHASE3
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
This study is looking at a new combination of medicines, capivasertib and fulvestrant, for women and men with a specific type of advanced breast cancer. It compares this combination to fulvestrant plus a dummy drug to see if it works better.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia